VANCOUVER, Sept. 22, 2017 /CNW/ - RepliCel Life Sciences
Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the
"Company"), a company developing next-generation technologies in
aesthetics and orthopedics, is pleased to announce that it has
retained Hybrid Financial Inc. ("Hybrid") to provide certain
investor relations services (the "Services") to the Company,
commencing September 26, 2017.
Under the terms of Hybrid's engagement (the "Engagement"),
RepliCel has agreed to pay Hybrid a monthly retainer of
CAD$15,000 for an initial term of six
months, with such retainer payable upon completion of RepliCel's
next financing. Upon completion of the initial six-month term,
RepliCel may extend the term of the Engagement on a month-to-month
basis.
The Engagement is subject to approval by the TSX Venture
Exchange.
Hybrid and/or its principals have an interest, directly or
indirectly, in RepliCel securities.
About RepliCel Life Sciences
RepliCel is a
regenerative medicine company focused on developing autologous cell
therapies that address conditions caused by a deficit of healthy
cells required for normal tissue healing and function. The
Company's product pipeline is comprised of three clinical-stage
products: RCT-01 for tendon repair, RCS-01 for skin
rejuvenation and RCH-01 for hair restoration. RCH-01 is under
exclusive license by Shiseido Company for certain Asian countries.
All product candidates are based on RepliCel's innovative
technology, utilizing cell populations isolated from a patient's
healthy hair follicles.
RepliCel is also developing a proprietary injection device
(RCI-02) optimized for the administration of its products and
licensable for use with other dermatology applications. Please
visit http://replicel.com/ for additional information.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE RepliCel Life Sciences Inc.